Abivax reports 2023 financial results and operational
Abivax reports 2023 financial results and operational update Raised EUR 500M in 2023, including a EUR 130M capital increase, two structured debt...
Stay updated with breaking news from Patrick Malloy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Abivax reports 2023 financial results and operational update Raised EUR 500M in 2023, including a EUR 130M capital increase, two structured debt...
PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients...
EQS-News: ABIVAX / Key word: Conference Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th...
EQS-News: ABIVAX / Key word(s): ConferenceAbivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO) 13.02.2024 / 08:30 CET/CESTThe issuer is solely responsible for the content o...
EQS-News: ABIVAX / Key word: Personnel Abivax appoints Ana Sharma as Vice President, Global Head of Quality 07.02.2024 / 08:30 CET/CEST The issuer is solely...